Prostate Cancer

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

Dr Stephen Freedland outlines the currently available, NCCN-recommended treatment options for patients with high-risk, clinically localized prostate cancer, and the clinical challenges he faces during the treatment decision-making process.

Stephen J. Freedland, MD, describes the process of diagnosing, grading, staging, and stratifying risk for patients with prostate cancer and the typical tests he uses in his clinical practice.

“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.

Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.

A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.

Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.

A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.

Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.

An expert comments on the patient profile and offers insights into how he approaches treatment and management of prostate cancer.

Gordon A. Brown, DO, presents the profile of a 60-year-old man with prostate cancer.

The device helps reduce unintentional side effects of prostate cancer therapy.

“We are seeing responses,” says Tanya Dorff, MD.

“The trial we're most interested in right now is the phase 3 VERACITY study of sabizabulin that was opened based on the results of this trial,” says Mark C. Markowski, MD, PhD.

“Guidelines are not a rulebook; they're a framework for how to think about a particular disease,” says Edward M. Schaeffer, MD, PhD.

Smilow Cancer Hospital offers the latest treatments for prostate cancer, including single-port robotic radical prostatectomy.

William J. Catalona, MD, explains how the approach of active surveillance in prostate cancer emerged alongside the advent of PSA screening.

The odds of a negative biopsy were 3.5 times higher when adding the androgen receptor pathway inhibitor to active surveillance.

“What was published in May of 2022 was version 4 of the 2022 guidelines,” says Edward M. Schaeffer, MD, PhD.

“I think most panelists are happy to participate in those meetings, because generally speaking, those ad hoc meetings are done because there's a new advance in the field,” says Edward M. Schaeffer, MD, PhD.

A recent cohort study assessed ADT durations for both patients receiving external beam radiotherapy (EBRT) alone and those treated with EBRT plus a brachytherapy boost.

A recent study showed the capacity to classify metastatic castration-resistant prostate tumors as luminal and basal, and examined the personalized medicine potential unlocked by identifying these subtypes.

“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.

"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.

“These analyses illustrate the critical role for inclusion of mathematical models, evolutionary first principles and computer simulations in trial design. Unlike conventional clinical trials, this approach allows both cohort and patient-specific analyses," said Jingsong Zhang, MD, PhD.

"What we still need to trial is the use of treatment intensification or triple therapy in men with high-risk localized and/or locally advanced disease," writes Michael S. Cookson, MD, MMHC.

"One of the main goals of our interactions with patients is to increase adherence," said Amy Pfeifer, PharmD, BCPS, CSP.

"We believe this novel treatment strategy will improve the lives of many prostate cancer patients,” said lead study investigator Behfar Ehdaie, MD.

The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.